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PDevice-Detected Atrial Tachyarrhythmias
Predict Adverse Outcome in Real-World
Patients With Implantable Biventricular Defibrillators
Massimo Santini, MD,* Maurizio Gasparini, MD,† Maurizio Landolina, MD,‡ Maurizio Lunati, MD,§
Alessandro Proclemer, MD, Luigi Padeletti, MD,¶ Domenico Catanzariti, MD,# Giulio Molon, MD,**
Giovanni Luca Botto, MD,†† Laura La Rocca, MS,‡‡ Andrea Grammatico, PHD,‡‡
Giuseppe Boriani, MD,§§ on behalf of the cardiological centers participating
in the ClinicalService Project
Rome, Rozzano, Pavia, Milano, Udine, Florence, Rovereto, Negrar, Como, and Bologna, Italy
Objectives The purpose of this analysis was to evaluate the correlation between atrial tachycardia (AT) or atrial fibrillation
(AF) and clinical outcomes in heart failure (HF) patients implanted with a cardiac resynchronization therapy
defibrillator (CRT-D).
Background In HF patients, AT and AF have high prevalence and are associated with compromised hemodynamic function.
Methods Forty-four Italian cardiological centers followed up 1,193 patients who received a CRT-D according to current
guidelines for advanced HF, New York Heart Association functional class II, left ventricular ejection fraction
35%, and QRS complex 120 ms. All patients were in sinus rhythm at implant.
Results During a median follow-up period of 13 months, AT/AF 10 min occurred in 361 of 1,193 (30%) patients. The
composite end point (deaths or HF hospitalizations) occurred in 174 of 1,193 (14.6%). Multivariate time-
dependent Cox regression analyses showed that composite end point risk was higher among patients with
device-detected AT/AF (hazard ratio [HR]: 2.16, p  0.032), New York Heart Association functional class III or IV
compared with II (HR: 2.09, p  0.002), and absence of beta-blockers (HR: 1.36, p  0.036). Furthermore, the
composite end point risk was inversely associated with left ventricular ejection fraction (HR: 1.04, p  0.045),
increasing by a factor of 4% for each 1% decrease in left ventricular ejection fraction.
Conclusions In HF patients with CRT-D, device-detected AT/AF is associated with a worse prognosis. Continuous device diagnostics
monitoring and Web-based alerts may inform the physician of AT/AF occurrences and identify patients at risk of car-
diac deterioration or patients with suboptimal rate or rhythm control. (Italian ClinicalService Project;
NCT01007474) (J Am Coll Cardiol 2011;57:167–72) © 2011 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.08.624A
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ccepted August 10, 2010.mong chronic heart failure (HF) patients, atrial tachycar-
ia (AT) or atrial fibrillation (AF) are common comorbidi-
ies and are associated with a worse prognosis (1–3). For
atients with HF, systolic dysfunction and cardiac dyssyn-
hrony, cardiac resynchronization therapy (CRT), through
iventricular pacing, reduces the risk of death, reduces
omplications, and improves symptoms and quality of life
4,5). Benefits of CRT have also been demonstrated in
atients with AT/AF (6,7).
Only a few studies have evaluated the incidence and
linical consequences of AT/AF in HF patients with
RT pacemakers (8) or CRT implantable cardioverter-
efibrillators (CRT-D) (9). Device diagnostics allows a
ontinuous monitoring of cardiac arrhythmias and an accu-
ate evaluation of AT/AF occurrence and duration. The aim
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Atrial Tachyarrhythmias Clinical Impact on CRT-D Patients January 11, 2011:167–72of our research was to characterize
patients’ AT/AF profiles, in terms
of maximum AT/AF duration,
and to evaluate the correlation be-
tween AT/AF and clinical out-
comes, such as survival or HF
hospitalizations, in a large popula-
tion of patients with CRT-D.
Methods
Patient population. Patients were
included consecutively by 44 car-
diological centers that participate
in the Italian ClinicalService
Project, a national medical care
project aiming to evaluate and im-
prove the use of implantable car-
diac devices in clinical practice.
Each patient signed an informed
consent approved by each site’s
nstitutional review board.
All patients received a CRT-D, according to current guide-
ines (10,11), namely, advanced HF (New York Heart
ssociation [NYHA] functional class II, III, or IV), de-
ressed left ventricular function (left ventricular ejection
raction [LVEF] 35%), and wide QRS complex (120
s). A history of AT/AF was defined as 1 AT/AF
pisode, documented by electrocardiogram or Holter mon-
tor, in the period preceding implantation. Patients with
ermanent AT/AF or treated by pulmonary vein AT/AF
blation were excluded from the analysis.
ollow-up and end points. In-hospital follow-up visits
ere scheduled according to each center’s clinical practice.
atients’ clinical management, such as treatment of AT/AF
pisodes, was performed according to expert cardiologists’
iscretion.
Information about clinical outcomes such as hospitaliza-
ions and deaths were collected during scheduled or un-
cheduled hospital visits, or by phone calls for patients who
issed programmed visits.
The incidence and duration of AT/AF was derived by
evice data, which comprise the total time spent by the
atient in AT/AF for each day of the follow-up period.
he AT/AF detection and its sensitivity and specificity,
n the CRT-D used, have been previously described (12).
atients were considered to have experienced AT/AF
pisodes if the device detected a cumulative AT/AF
uration 10 min in a day, a cut-off duration recognized
s appropriate to discard false detections (8). As a
unction of the duration of the longest AT/AF period,
bserved during the follow-up period, each patient was
lassified according to 5 AT/AF profiles, whose length
as 10 min, 6 h, 24 h, 7 days, and 6 months;
Abbreviations
and Acronyms
AF  atrial fibrillation
AT  atrial tachycardia
BIVP%  biventricular
pacing percentage
CI  confidence interval
CRT  cardiac
resynchronization therapy
CRT-D  cardiac
resynchronization therapy
defibrillator
HF  heart failure
HR  hazard ratio
LVEF  left ventricular
ejection fraction
NYHA  New York Heart
Associationhe first 3 cut-offs characterize different forms of parox- Bsmal AT/AF, whereas the last 2 mimic persistent and
ermanent AT/AF, respectively.
Biventricular pacing percentage (BIVP%) was estimated
s the number of paced biventricular beats divided by the
umber of paced or sensed ventricular beats over given time
eriods; in particular, BIVP% was estimated both during
he whole lifetime of the device and during AT/AF periods.
evice programming. The pacing mode was atrial-
ynchronous ventricular pacing. The automatic mode-
witch feature was enabled in all patients to switch the
acing mode to a nonatrial tracking mode during AT/AF.
he detection and therapy programming of the defibrillator
as left to the clinical practice of each center.
tatistical analysis. Descriptive statistics were reported as
ean and standard deviation for normally distributed con-
inuous variables, or median with 25th and 75th percentiles
n the case of skewed distribution. Categorical variables
ere reported as percentages. Comparisons of categorical
ariables were performed by means of the Fisher exact test
r chi-square, as appropriate.
Survival analysis was performed by the Kaplan-Meier
ethod, and the log-rank test was applied to evaluate
ifferences between survival trends.
Hazard ratios (HRs) and their 95% confidence intervals
CIs) were computed by means of time-dependent Cox
egression models, where AT/AF during follow-up was
onsidered as a time-dependent covariate and baseline
redictors as fixed covariates. After checking for collinearity,
e included in the multivariate Cox models any baseline
ariable with p  0.05 on univariate analysis, and age and
ex regardless of their p values. For statistical analysis,
tata/SE version 11.0 for Windows (StataCorp LP, College
tation, Texas) were used.
esults
he baseline characteristics of the 1,193 patients are shown
n Table 1.
T/AF type and incidence during follow-up. The me-
ian follow-up period was 13 months (25th and 75th
ercentile: 8 and 20 months). AT/AF lasting longer than 10
in occurred in 361 of 1,193 (30%) patients. Figure 1 shows
he number of patient with AT/AF occurrence, as a func-
ion of their AT/AF profile. Among 882 patients with no
revious history of AT/AF, 178 (20%) had a new-onset
T/AF.
linical outcomes. The incidences of the composite end point
nd its components—deaths and heart failure hospitalizations—
re summarized in Table 2, for various patient subgroups
dentified as a function of AT/AF occurrence, duration, and
ype.
Table 3 shows results of multivariate time-dependent
ox regression analyses performed to evaluate predictors of
eath, HF hospitalizations and the composite end point. In
he whole population, the median value of the lifetime
IVP% was 98% (25th and 75th percentiles: 95% and 99%).
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January 11, 2011:167–72 Atrial Tachyarrhythmias Clinical Impact on CRT-D Patientsn patients with AT/AF, it was 95% (91% and 99%) during
he whole follow-up period, and more particularly, 98%
95% and 99%) during sinus rhythm and 71% (51% and
2%) during AT/AF (p  0.01 vs. sinus rhythm period). In
atients with AT/AF occurrence, the condition of nonop-
aseline Patient Characteristics (n  1,193)Table 1 Baseline Patient Characteristics (n  1,193)
Male 939 (79%)
Age, yrs 66 10
Secondary prevention 207 (17%)
Hypertension 557 (47%)
Ischemic cardiopathy 576 (49%)
AT/AF history 310 (26%)
Valve disease 119 (10%)
Diabetes mellitus 260 (22%)
NYHA functional class II 453 (38%)
NYHA functional class III 710 (60%)
NYHA functional class IV 30 (2%)
QRS interval, ms 149 31
LVEF, % 27 6
LVEDD, mm 69 10
LVESD, mm 58 11
LVEDV, ml 207 68
LVESV, ml 154 56
Beta-blockers 859 (72%)
ACE inhibitors 871 (73%)
Diuretics 1,157 (97%)
Amiodarone 370 (31%)
Anticoagulant agents 286 (24%)
Antiplatelet agents 501 (42%)
CE angiotensin-converting enzyme; AF atrial fibrillation; AT atrial tachycardia; LVEDD left
entricle end-diastolic diameter; LVEDV  left ventricle end-diastolic volume; LVEF  left ventricle
jection fraction; LVESD  left ventricle end-systolic diameter; LVESV  left ventricle end-systolic
olume; NYHA  New York Heart Association.
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Figure 1 Patients With AT/AF as Function of AT/AF Profile
Number of patients with atrial tachycardia (AT) or atrial fibrillation (AF) as a functio
AT/AF episode of that patient. Solid red sections identify patients with known histimal CRT, namely, lifetime BIVP% 95%, was found to
e an independent predictor of clinical outcomes, associated
ith a higher risk of the composite end point (HR: 2.0, 95%
I: 1.00 to 4.05, p  0.05), of death (HR: 6.6, 95% CI:
.70 to 25.63, p  0.006), and of HF hospitalization (HR:
.14, 95% CI: 1.36 to 7.25, p  0.007).
The Kaplan-Meier survival analyses showed higher inci-
ences of both the composite end point and HF hospital-
zations among patients with AT/AF during follow-up
hen compared to patients without AT/AF, as shown in
igure 2.
iscussion
eal-life registries have an important role in identifying
ovel risk factors. The present analysis adds to the previous
iterature in that it shows the impact of device-detected
T/AF on adverse clinical outcomes, associating this im-
act with specific AT/AF profiles and with suboptimal
RT.
mpact of AT/AF on clinical outcomes. Device-detected
T/AF was significantly correlated with the composite
nd point (death or HF hospitalizations) at multivariate
ime-dependent Cox regression analysis, at Kaplan-
eier survival analysis, and by simple proportion analysis
est. The explanation for these findings may be that
T/AF causes loss of atrial systole, irregular ventricular
hythm, and tachycardia-related contractile dysfunction.
oreover, in CRT-D recipients, AT/AF may worsen a
atient’s health by dramatically reducing biventricular
acing; in fact, BIVP% achieved 98% during sinus
hythm and only 71% during AT/AF. A BIVP% 95%
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Atrial Tachyarrhythmias Clinical Impact on CRT-D Patients January 11, 2011:167–72as significantly associated with both HF hospitaliza-
ions and death.
ummary of knowledge from previous studies. The impor-
ance of BIVP% has been shown by Gasparini et al. (6,7) in
RT patients with permanent AT/AF by comparing atrio-
entricular node ablation versus pharmacological rate control,
atients With Clinical End Points as a Function of AT/AF OccurrenTable 2 Patients With Clinical End Points as a Function of AT/
End Points
Dea
n  54
No AT/AF during follow-up (n  832) 34 (4.
AT/AF during follow-up (n  361) 20 (5.
10 min  AT/AF 6 h (n  100) 2 (2%
6 h  AT/AF 24 h (n  57) 4 (7.
1 day  AT/AF 7 days (n  49) 3 (6.
7 days  AT/AF 6 months (n  122) 7 (5.
AT/AF 6 months (n  33) 4 (12
Patients in SR before implant and during follow-up (n  704) 30 (4.
New-onset AT/AF (n  178) 5 (2.
Patients with AT/AF history but SR during follow-up (n  128) 4 (3.
Patients with AT/AF before and after implant (n  183) 15 (8.
p  0.005 versus patients without AT/AF during follow-up. †p  0.0005 versus patients without
Abbreviations as in Table 1.
linical Variables Associatedth C inical Outcomes According toultiv riate Time-Dep ndent Cox Regression Models
Table 3
Clinical Variabl s Associated
With Clinical Outcomes According to
Multivariate Time-Dependent Cox Regression Models
Patient Characteristics HR 95% CI p Value
Composite end point
Male 1.02 0.63–1.65 0.939
Age 1.01 0.99–1.04 0.198
AT/AF history 0.94 0.58–1.52 0.808
AT/AF during follow-up* 2.16 1.07–4.38 0.032
NYHA functional class III or IV versus II 2.09 1.30–3.36 0.002
Low LVEF† 1.04 1.01–1.07 0.045
Absence of beta-blockers 1.36 1.03–1.57 0.036
Heart failure hospitalization
Male 1.10 0.64–1.88 0.727
Age 1.02 0.99–1.04 0.216
AT/AF history 0.89 0.52–1.54 0.686
AT/AF during follow-up* 1.98 0.92–4.24 0.079
NYHA functional class III or IV versus II 1.86 1.10–3.14 0.021
Low LVEF† 1.05 1.01–1.08 0.023
Absence of beta-blockers 1.42 1.07–1.63 0.023
Death
Male 1.39 0.60–3.18 0.442
Age 1.01 0.97–1.05 0.685
AT/AF history 0.78 0.43–1.41 0.412
AT/AF during follow-up* 1.64 0.93–2.89 0.086
NYHA functional class III or IV versus II 2.04 0.86–4.86 0.106
Low LVEF† 1.01 0.95–1.07 0.796
Absence of beta-blockers 1.42 0.27–1.26 0.170
Secondary prevention 2.21 1.05–4.69 0.038
Oral anticoagulant therapy 2.06 1.00–4.28 0.051
AT/AF during follow-up was considered in the Cox regression model as a time-dependent variable.
Left ventricular ejection fraction (LVEF) was considered as a continuous variable (i.e., the hazard
atio (HR) of 1.04 for the composite end point means that for each 1% decrease of LVEF the risku
f the composite end point increases by a factor of 4%.
Abbreviations as in Tables 1 and 2.pparently achieving adequate biventricular pacing. These
uthors showed that atrioventricular node ablation, ensuring
00% effective CRT, was associated with significant improve-
ent in left ventricular function and volumes, exercise capacity,
nd mortality.
Our results indicating that AT/AF occurrence during
ollow-up is an independent predictor of adverse clinical
vents contribute and extend the discussion of whether
T/AF is independently associated with a worse outcome
1–3,6–9). Benjamin et al. (1) showed that patients in who
T/AF developed during 40 years of follow-up of the
ramingham Heart Study cohort were associated with a
.9-fold mortality risk. More recently, the CARE-HF
Cardiac Resynchronization in Heart Failure) trial (8)
howed that patients who had AT/AF presented with
igher rates of deaths or unplanned cardiovascular hospital-
zations. Evaluating this correlation, the CARE-HF study
8) authors only considered AT/AF as documented by
lectrocardiography, whereas our findings extend the corre-
ation with death or HF hospitalizations to device-detected
T/AF.
Borleffs et al. (9) studied CRT-D patients with no AT/AF
istory and showed that new-onset AT/AF was associated
ith a higher incidence of cardiac hospitalizations. Our data
onfirm and extend this finding since we found that any
T/AF occurrence, new-onset or recurrence, correlated with a
igher incidence of HF hospitalizations.
linical relevance of AT/AF duration assessment. Pa-
ients with persistent or permanent AT/AF had higher
ncidences of the composite end point or HF hospitalization
hen compared with patients in sinus rhythm. This finding
ay be explained by the negative impact of a prolonged
RT loss due to AT/AF-induced high spontaneous ven-
ricular rate.
Figure 1, showing that many new-onset AT/AF episodes
ave long duration, suggests that this population is at high
isk of embolic complications and may benefit from contin-
d Durationccurrence and Duration
)
Heart Failure Hospitalizations
n  136 (11.4%)
Composite End Point
n 174 (14.6%)
77 (9.2%) 101 (12.1%)
59 (16.3%)* 73 (20.2%)*
12 (12%) 15 (15.0%)
6 (10.5%) 9 (15.8%)
5 (10%) 9 (18.4%)
26 (21.3%)† 30 (24.6%)†
10 (30.3%)† 10 (30.3%)*
65 (9.2%) 85 (12.1%)
28 (15.7%)‡ 33 (18.5%)‡
12 (9.4%) 16 (12.5%)
31 (16.9%)‡ 40 (21.9%)‡
during follow-up. ‡p  0.05 versus patients in sinus rhythm (SR) during follow-up.ce anAF O
ths
(4.5%
1%)
5%)
)
0%)
1%)
7%)
.1%)‡
3%)
8%)
1%)
2%)ous AT/AF monitoring.
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January 11, 2011:167–72 Atrial Tachyarrhythmias Clinical Impact on CRT-D Patientstudy limitations. Our results may not be extended to a
eneral, nondevice, HF population and, in particular, not to
F patients without CRT.
onclusions
or HF patients treated with CRT-D, device-detected
T/AF was correlated with worse prognosis in terms of deaths
r HF hospitalizations. In particular, this association appeared
ainly mediated by the subgroup of patients with persistent
T/AF, because of the negative impact of a prolonged CRT
oss caused by AT/AF-induced high ventricular rate.
These correlations suggest that AT/AF continuous mon-
toring may be a useful tool for identifying patients at risk of
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Figure 2 Kaplan-Meier Curves
Kaplan-Meijer curves show freedom from (A) the end point composed of death or
patients with atrial tachycardia or atrial fibrillation (AT/AF) (red lines) versus patienardiac deterioration or patients with suboptimal rate orhythm control. AT/AF occurrences may trigger re-
valuation of current treatment and, if appropriate, phar-
acological or electrical interventions to control ventricular
ate, such as pharmacological blockade or ablation of the
trioventricular node conduction.
Our findings suggest the importance of utilizing contin-
ous device monitoring and Web-based care alerts based on
T/AF duration or on ventricular rate or BIVP% during
T/AF.
eprint requests and correspondence: Dr. Massimo Santini,
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